Loading
Vicarious Surgical Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Khosla Ventures V, L.P., was filed 09 Aug 2023.
Vicarious Surgical Inc.: what insiders have been doing
This page follows insider dealings at Vicarious Surgical Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. 2 insiders have disclosed 6 filings since 21 October 2025.
The flow runs one way only: 6 sales worth €8,264, from 2 insiders, and no purchase. One trade stands out by size: a sale of €1,920 from Sachs Adam David, disclosed on 21 November 2025.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,454 companies tracked on its exchange, the median is 22 filings; at 6 filings, this issuer sits below that mark. Our records for Vicarious Surgical Inc. go back to 2021, with 21 purchases and 166 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -50.2 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
290
Thresholds
n/a
Buy Volume
€12M
21 ops. · all time
Sell Volume
€2M
166 ops. · all time
Who traded when
BuySaleAdam David Sachs14 sales
Sammy Khalifa14 sales
William John Kelly3 sales
Donald F. Tang2 sales
John Mazzola2 sales
Since the insiders bought
- -77.9%Entry US$27.48 · Close at T+365 US$6.07
- -86.2%Entry US$62.10 · Close at T+365 US$8.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.02
Analyst consensus
Income statement
EBITDA-US$49.5M
Net income-US$50.2M0.0% margin
Valuation
P/Book0.0x
Beta2.16
Balance sheet & cash
Market capUS$128.4k
Total debtUS$7.8M
Free Cash Flow-US$45.2M
Debt / Equity202%
Profitability & ownership
ROE-223.8%
ROA-79.0%
% insiders14.8%
% institutions14.9%
Last declaration on 24 February 2026
Declarations290 total
754 shares@ US$2.08410.3% of flowClass A Common StockSEC:0001213900-26-019943:0
942 shares@ US$2.08780.3% of flowClass A Common StockSEC:0001213900-26-019944:0
463 shares@ US$2.9520.2% of flowClass A Common StockSEC:0001213900-25-118410:0
239 shares@ US$2.970.1% of flowClass A Common StockSEC:0001213900-25-118409:0
653 shares@ US$2.7440.3% of flowClass A Common StockSEC:0001213900-25-113763:0
816 shares@ US$2.7150.4% of flowClass A Common StockSEC:0001213900-25-113762:0
463 shares@ US$5.75640.4% of flowClass A Common StockSEC:0001213900-25-084550:0
239 shares@ US$5.71950.3% of flowClass A Common StockSEC:0001213900-25-084549:0
2,753 shares@ US$6.696596.5% of flowClass A Common StockSEC:0001213900-25-081179:0
653 shares@ US$6.04220.7% of flowClass A Common StockSEC:0001213900-25-079495:0
817 shares@ US$6.03120.8% of flowClass A Common StockSEC:0001213900-25-079494:0
100 shares@ US$6.683.5% of flowClass A Common StockSEC:0001213900-25-079492:0
279 shares@ US$7.79960.4% of flowClass A Common StockSEC:0001213900-25-057361:0
223 shares@ US$7.81450.3% of flowClass A Common StockSEC:0001213900-25-057359:0
239 shares@ US$7.25090.3% of flowClass A Common StockSEC:0001213900-25-051100:0
463 shares@ US$7.21930.5% of flowClass A Common StockSEC:0001213900-25-051099:0
653 shares@ US$7.52241.0% of flowClass A Common StockSEC:0001213900-25-046364:0
817 shares@ US$7.52771.0% of flowClass A Common StockSEC:0001213900-25-046363:0
129 shares@ US$7.97070.2% of flowClass A Common StockSEC:0001013762-25-001639:0
161 shares@ US$7.91960.2% of flowClass A Common StockSEC:0001013762-25-001641:0
264 shares@ US$10.277117.7% of flowClass A Common StockSEC:0001213900-25-020275:0
276 shares@ US$10.25250.6% of flowClass A Common StockSEC:0001213900-25-020276:0
535 shares@ US$10.27911.0% of flowClass A Common StockSEC:0001213900-25-020272:0
943 shares@ US$14.53322.5% of flowClass A Common StockSEC:0001213900-25-016007:0
754 shares@ US$14.53052.3% of flowClass A Common StockSEC:0001213900-25-016006:0
25 of 290 declarations
About Vicarious Surgical Inc.
Vicarious Surgical Inc. is a U.S.-based medical robotics company listed on the American market, specifically associated with the NYSE/NASDAQ universe through ticker RBOTW, and headquartered in Waltham, Massachusetts, United States. The company was founded in 2014 and is developing a next-generation surgical robotics platform focused on minimally invasive procedures. From an equity research perspective, Vicarious Surgical is best viewed as a disruptive early-stage medtech developer trying to challenge the economics and usability of established robotic surgery systems. Its strategic goal is to expand access to robotic surgery while improving procedural efficiency and, ultimately, helping lower healthcare costs. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai))
The company’s core business is the design and advancement of a proprietary surgical robot rather than a mature, scaled commercial franchise. That matters for investors: the story is driven less by current sales and more by product development milestones, clinical validation, regulatory progress, capital discipline, and eventual hospital adoption. In other words, Vicarious Surgical carries the hallmark risk/reward profile of an early commercial or pre-commercial healthcare robotics name. Upside depends on proving that its system can deliver differentiated clinical and economic value in real-world operating environments. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai))
Read moreShow less
Competitively, the company operates in a market led by much larger and better-capitalized players, most notably Intuitive Surgical. Vicarious Surgical is trying to stand out through a different robotics architecture and a value proposition centered on better dexterity, improved visualization, enhanced surgeon ergonomics, and potentially lower total procedure cost. That disruptive positioning is interesting, but it also means execution risk is high. The market will want to see evidence of engineering readiness, repeatable performance, safety, and a credible pathway to commercialization before assigning a durable premium valuation. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai))
Geographically, the business is primarily U.S.-centered, with its headquarters and principal corporate presence in Massachusetts. Public disclosures and investor communications indicate that the company remains focused on the United States for its core operations and capital-markets outreach. The company’s investor relations materials, earnings releases, and conference participation also suggest a narrative still anchored in development and financing rather than broad international sales. That is typical for a robotics platform company at this stage of its lifecycle. ([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai))
Recent updates through 2025 and 2026 have emphasized cash burn management, quarterly financial results, and ongoing engagement with the investment community. Those disclosures are important because they frame the company’s near-term priorities: preserving liquidity, advancing the platform, and maintaining optionality for future commercialization. Insider Form 4 activity has also been visible in the market, which often draws attention among small-cap investors trying to gauge management sentiment. Overall, RBOTW remains a speculative healthcare robotics name tied to technology execution, financing needs, and the company’s ability to convert a promising concept into a commercially viable surgical system. ([stocktitan.net](https://www.stocktitan.net/sec-filings/RBOT/form-4-vicarious-surgical-inc-insider-trading-activity-bd58b7e8dadf.html?utm_source=openai))
